13F Data
13F filer · CIK 1917529

Atlas Venture Life Science Advisors, LLC

CAMBRIDGE, MA · filing since Q4 2021 · last filing Aug 13, 2026
Reported value
$881.3M
+$91.3M vs prior
Positions
7
New / sold out
1 / 0
Added / reduced
1 / 3
Turnover
14.6%
buys $121.9M · sells $252.5M
Top-10 weight
100.0%

Biggest buys vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
NewKailera Therapeutics, Inc.+5,171,282–+$113.9M
AddedQ32 Bio, Inc.+625,000+29.9%+$8.0M

Biggest sells vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
ReducedKymera Therapeutics, Inc.-1,730,467-37.8%$-198.4M
ReducedDyne Therapeutics, Inc.-2,330,366-25.5%$-51.8M
ReducedKorro Bio, Inc.-174,265-15.3%$-2.3M

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q4 2021: $1.1BQ1 2022: $791.0MQ2 2022: $598.2MQ3 2022: $906.2MQ4 2022: $830.2MQ1 2023: $738.6MQ2 2023: $803.6MQ3 2023: $645.6MQ4 2023: $839.8MQ1 2024: $1.1BQ2 2024: $949.6MQ3 2024: $1.1BQ4 2024: $819.7MQ1 2025: $521.8MQ2 2025: $662.4MQ3 2025: $752.6MQ4 2025: $865.2MQ1 2026: $790.0MQ2 2026: $881.3M
Q4 2021Q2 2026

Holdings · Q2 2026

#SecuritySharesValueWeight
1Kymera Therapeutics, Inc.COMMON STOCK2,847,541$326.5M37.05%
2Dyne Therapeutics, Inc.COMMON STOCK6,800,099$151.0M17.14%
3Sionna Therapeutics, Inc.COMMON STOCK2,995,602$131.8M14.95%
4Kailera Therapeutics, Inc.COMMON STOCK5,171,282$113.9M12.93%
5Disc Medicine, Inc.COMMON STOCK1,513,875$110.7M12.56%
6Q32 Bio, Inc.COMMON STOCK2,717,106$34.6M3.93%
7Korro Bio, Inc.COMMON STOCK962,884$12.7M1.44%